Understanding Glioblastoma: Advances in MRI and Clinical Trial Criteria

Glioblastoma multiforme (GBM) is the most malignant and prevalent subtype of glioma, representing the most common primary brain tumor in adults. MRI is considered the gold standard for assessing glioblastoma. However, structural MRI alone is insufficient for accurately interpreting treatment-related changes. This post explores the evolving landscape of medical imaging for GBM, focusing on the recent advancements that improve treatment assessment and patient outcomes.

GBM accounts for 15% of all primary CNS tumors and 50% of malignant primary CNS tumors and poses significant treatment challenges due to its aggressive nature and poor prognosis. Surgical resection can be complicated by the tumor’s location, necessitating careful techniques to preserve healthy brain tissue. Assessment of MRI, the gold standard for GBM imaging, has been enhanced by new criteria like RANO 2.0, which simplifies response assessment across various therapies and reduces confusion in clinical trials.

Medical imaging is critical for assessing treatment responses in GBM patients. The original Response Assessment in Neuro-Oncology (RANO) criteria has been enhanced over the years, with updates like iRANO and mRANO addressing specific challenges in immunotherapy and recurrent glioblastoma. RANO 2.0, published in 2023, seeks to unify various assessment protocols, allowing for volumetric measurements and improving evaluations of non-enhancing disease. This new approach also shifts the baseline to post-radiotherapy MRI, enhancing accuracy during the high-risk period following treatment initiation.

Additionally, advanced MRI techniques as described below provide critical information about tumor characteristics and treatment response.

• Perfusion-weighted Imaging (PWI): Helps assess blood flow and vascularity within tumors, aiding assessment of tumor progression, differentiating recurrent tumor from delayed radiation necrosis, and helping to distinguish between pseudo-progression and true progression or recurrent GBM.
• Diffusion Tensor Imaging (DTI): Measures the diffusion of water molecules in tissues, providing insights into cellularity and integrity of brain structures, for purposes such helping to distinguish between tumor progression and treatment-related changes.
• Magnetic Resonance Spectroscopy (MRS): Analyzes metabolic changes, revealing the presence of specific metabolites associated with tumor activity and assists with differentiating tumor grades.
• Longitudinal Monitoring: By segmenting treatment history into phases, advanced imaging techniques provide tailored insights at each stage.

Dr Nabil El-Shafeey, Medical Director at Imaging Endpoints explained: “RANO 2.0 is expected to improve accuracy in progression evaluation and reduce variability in imaging interpretations, ultimately enhancing patient outcomes in GBM trials while supporting the development of more effective therapies.”

Looking to the future, Imaging Endpoints is pleased to offer RANO 2.0 on our glioblastoma studies. Imaging Endpoints is the global leader in designing imaging protocols for clinical trials in glioblastoma, boasting a flawless inspection record and a remarkable 95% marketing success rate across all trials.

To connect with our experienced medical and scientific professionals to explore how our tailored imaging solutions can support your GBM clinical trials.